Table of Contents
Journal of Neurodegenerative Diseases
Volume 2013 (2013), Article ID 679089, 4 pages
http://dx.doi.org/10.1155/2013/679089
Clinical Study

Cerebrospinal Fluid Biomarkers for Kii Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex

1Medical Department, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan
2Department of Neurology, Tokyo Metropolitan Geriatric Hospital, 35-2 Sakaemachi, Itabashi-ku, Tokyo 173-0015, Japan
3Department of Medical Welfare, Suzuka University of Medical Science, 1001-1 Kishioka-cho, Suzuka City, Mie 510-0293, Japan
4Department of Neurology, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan

Received 16 January 2013; Accepted 6 March 2013

Academic Editor: Peter Crouch

Copyright © 2013 Yui Nakayama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. Amyotrophic lateral sclerosis/parkinsonism-dementia complex is classified as one of the tauopathies. Methods. The total tau, phosphorylated tau, and amyloid β42 levels were assayed in cerebrospinal fluid from patients with Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex ( ), Alzheimer’s disease ( ), Parkinson’s disease ( ), amyotrophic lateral sclerosis ( ), and controls ( ) using specific enzyme-linked immunosorbent assay methods. Results. Total tau and phosphorylated tau did not increase and amyloid β42 was relatively reduced in Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex. Relatively reduced amyloid β42 might discriminate Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex from amyotrophic lateral sclerosis and Parkinson’s disease, and the ratios of phosphorylated-tau to amyloid β42 could discriminate Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex from Alzheimer’s disease. Conclusions. Cerebrospinal fluid analysis may be useful to differentiate amyotrophic lateral sclerosis/parkinsonism-dementia complex from Alzheimer’s disease, amyotrophic lateral sclerosis, and Parkinson’s disease.